Incyte's (INCY, $85.97) clinical trial disappoints
Incyte Corporation shares took a hit late trading Thursday, after news of disappointing results on one of its clinical trials.
The pharmaceutical company revealed that one of its drugs fell short of meeting its primary endpoint in a phase 3 trial. According Incyte’s statement, its JAK1 inhibitor itacitinib in combination with corticosteroids, “did not statistically improve overall response rate or non-relapse mortality” in patients with acute graft-versus-host disease. That is, it did not meet the primary endpoint of a statistically significant improvement in overall response rate (ORR) at Day 28 compared to placebo plus corticosteroids; also, no difference was found in non-relapse mortality at month 6, which is a crucial secondary endpoint.
The above-mentioned disease is often seen in patients undergoing bone marrow or organ transplants. Results of the trial will be submitted at a future medical conference.
Incyte shares were down around -10% after hours.
INCY in upward trend: price rose above 50-day moving average on June 03, 2026
INCY moved above its 50-day moving average on June 03, 2026 date and that indicates a change from a downward trend to an upward trend. In of 43 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are .
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INCY's RSI Indicator exited the oversold zone, of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .
The Momentum Indicator moved above the 0 level on June 03, 2026. You may want to consider a long position or call options on INCY as a result. In of 99 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .
The Moving Average Convergence Divergence (MACD) for INCY just turned positive on June 04, 2026. Looking at past instances where INCY's MACD turned positive, the stock continued to rise in of 36 cases over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where INCY advanced for three days, in of 325 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 229 cases where INCY Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INCY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
INCY broke above its upper Bollinger Band on June 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. INCY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.638) is normal, around the industry mean (19.817). P/E Ratio (14.460) is within average values for comparable stocks, (36.300). Projected Growth (PEG Ratio) (0.359) is also within normal values, averaging (1.691). INCY has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.039). P/S Ratio (3.874) is also within normal values, averaging (355.038).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a developer of drugs
Industry Biotechnology
Advertisement